Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jag2 siRNA
- Development stage
- Unknown
- Lead developer
- MedChemExpress
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
Jag2 siRNA is a research-grade small interfering RNA (siRNA) reagent designed to silence the expression of the Jagged-2 (JAG2) gene, which encodes a ligand for the Notch signaling pathway. By utilizing the RNA interference (RNAi) mechanism, this molecule specifically targets and facilitates the degradation of JAG2 mRNA transcripts, thereby reducing the production of the Jagged-2 protein. It is widely used in preclinical molecular biology and oncology research to study the role of Notch signaling in cell proliferation, differentiation, and disease progression. Common research areas include various cancers (such as colorectal cancer and medulloblastoma) and vascular conditions like hypoxic pulmonary arterial hypertension. It is not a proprietary therapeutic drug but is commercially available from laboratory reagent suppliers like MedChemExpress and Dharmacon.
- Other names
- Jagged-2 siRNAJagged2 siRNAJagged 2 siRNAJAG2 small interfering RNAJAG-2 small interfering RNAJAG 2 small interfering RNAJAG2 siRNAJAG-2 siRNAJAG 2 siRNA
02
Targets
JAG2 (JAG2 Notch ligand)
Beyond the preview
Go deeper on Jag2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jag2 siRNA.